Its also helped in so many other ways
J Cell Biochem 104:13561363 Kawanishi N, Sugimoto T, Shibata J, Nakamura K, Masutani K, Ikuta M, Hirai H (2006) Structure-based drug design of a highly potent CDK1, 2, 4, 6 inhibitor with novel macrocyclic quinoxalin-2-one structure
The FDA has a long-standing practice of sorting nominated ingredients into categories, and for the most favorable category it generally says it will not take action against a pharmacy that compounds with that ingredient while the formal process plays out, as long as the pharmacy meets the other legal conditions, he explains
While current treatments delay the progression of DCM to some extent, their effectiveness and safety remain limited
Fouad K, Pedersen V, Schwab ME, Brsamle C
Madzarac G et al